Related references
Note: Only part of the references are listed.Pulmonary marginal zone B-cell lymphoma of MALT type-What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study
Sung Yong Oh et al.
ANNALS OF HEMATOLOGY (2010)
Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study
Sung Yong Oh et al.
CANCER SCIENCE (2010)
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma
Enrico Orciuolo et al.
LEUKEMIA RESEARCH (2010)
Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases
Sung Yong Oh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Combination Therapy With Rituximab and Intravenous or Oral Fludarabine in the First-Line, Systemic Treatment of Patients With Extranodal Marginal Zone B-cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Type
Antonio Salar et al.
CANCER (2009)
Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
Robert Marcus et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study
Sung Yong Oh et al.
CANCER LETTERS (2007)
Intestinal marginal zone B-cell lymphoma of MALT type: clinical manifestation and outcome of a rare disease
Sung Yong Oh et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2007)
Rituximab and chlorambucil as first-line treatment for low-grade ocular adnexal lymphomas
Luigi Rigacci et al.
ANNALS OF HEMATOLOGY (2007)
Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases
Sung Yong Oh et al.
AMERICAN JOURNAL OF HEMATOLOGY (2007)
Nodal marginal zone B-cell lymphoma: analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma
Sung Yong Oh et al.
ANNALS OF HEMATOLOGY (2006)
Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage II and IV low-grade malignant non-Hodgkin's lymphoma
A Hagenbeek et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
K Tobinai et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Long-term follow-up of a randomized trial of fludarabine-mitoxantrone, compared with cyclophosphamide, doxorubicin, vindesine, prednisone (CHVP), as first-line treatment of elderly patients with advanced, low-grade non-Hodgkin's lymphoma before the era of monoclonal antibodies
C Foussard et al.
ANNALS OF ONCOLOGY (2005)
CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma
R Marcus et al.
BLOOD (2005)
Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients
SY Ma et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma
PL Zinzani et al.
CANCER (2004)
Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type
A Conconi et al.
BLOOD (2003)
Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue
E Zucca et al.
BLOOD (2003)
Treatment of Waldenstrom's macroglobulinemia with rituximab
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Stage I and II malt lymphoma: Results of treatment with radiotherapy
RW Tsang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2001)
Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma
JM Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation
G Meloni et al.
ANNALS OF ONCOLOGY (2000)
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
JM Foran et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
